NCT07612943Not yet recruiting
ProspectiveMaleAYA - Frequency and Prediction of Therapy-induced Testicular Dysfunction in AYA Cancer Survivors
Frequency and Prediction of Therapy-induced Testicular Dysfunction in AYA Cancer Survivors (ProspectiveMaleAYA)
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
This study describes the ProspectiveMaleAYA cohort, a multicentre, prospective, longitudinal European study designed to investigate the long-term impact of cancer and cancer treatments on reproductive and endocrine health in adolescent and young adult (AYA) male cancer patients. Addressing major gaps in standardized prospective data, particularly for long-term fertility, hypogonadism, and the effects of newer systemic therapies, the study will harmonize data collection across centres and follow patients from diagnosis through post-treatment survivorship. Comprehensive clinical, oncologic, reproductive, hormonal, biological, and patient-reported outcomes will be collected at predefined intervals to evaluate testicular dysfunction, fertility impairment, oligo/azoospermia, sexual health, and quality of life. Sub-cohorts will enable focused analyses of genetic and epigenetic sperm changes, whole-genome sequencing to identify susceptibility to reproductive and organ toxicity, accelerated aging markers following specific treatments, access to and satisfaction with fertility counselling, and sexual health dysfunctions. The overarching aim is to identify risk factors and predictive markers, develop individualized risk stratification and prediction models, and support precision, patient-centred survivorship care for male AYA cancer survivors.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 20 May 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 31 May 2030
- Lead sponsor
- Karolinska Institutet
- Diseases
- Childhood cancers
- NCT number
- NCT07612943
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Jun 2026 to the primary completion date, 31 May 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- subjects who were not treated with oncological treatment
- patients with a diagnosis of azoospermia or testicular failure previously to cancer diagnosis
Other illness
- individuals presenting with relapse or secondary cancers at time of inclusion
Other
- subjects who underwent bilateral orchiectomy
Who the study is looking for
- Subjects with male internal and external genitalia
- Age at cancer diagnosis 15-39 years old
- Subjects planned to or having received oncologic treatment
- Subjects able to provide semen sample
- Information available on cancer treatment and medical history
- Patients (or parents in case of minors) who signed informed consent
Age in the registry: 15 years to 39 years · Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.